Monday, September 30, 2013
Life Technologies, a global biotechnology company, has launched EZQC Online, a web-based tool for quality control management in molecular diagnostic labs. EZQC Online contains three modules: a guidance tool for initial validation and verification of molecular tests, a tool to help labs meet CLIA standards for calibration verifications and a tool for ongoing quality control monitoring that provides an opportunity for peer-to-peer comparisons.
Gliknik, a privately-held biopharmaceutical company, has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, Gliknik’s recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.
Global CRO Parexel International has launched Parexel Dĭng Huī, China Trials Solution. The offering combines advanced technology and international SOPs (Standard Operating Procedures) with local experience and resources to deliver cost-effective services that meet global quality standards. Parexel Dĭng Huī will support clients through locally delivered, streamlined services that support single-country registration trials and are tailored to meet Chinese NDA submission requirements.
A growing disease burden, universal coverage and good access to healthcare facilities are boosting the U.K. healthcare market, but increasing use of generics and government cost-cutting measures to reduce expenditure are restricting further growth, according to research and consulting firm GlobalData.
H. D. Smith, a pharmaceutical wholesaler and services provider based in Springfield, Ill., has acquired Triplefin, a reimbursement, patient assistance and pharmaceutical brand-support services company headquartered in Cincinnati, Ohio. H. D. Smith secured majority representation on Triplefin’s board of directors in January and majority stock ownership interest in May. H.D. Smith has now acquired the remaining 49% of Triplefin shares, giving the company full ownership.
Transcept Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of proprietary products to address therapeutic needs in neuroscience, and Shin Nippon Biomedical Laboratories (SNBL) have entered into an exclusive worldwide licensing agreement for a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug.
National nonprofit CureDuchenne has launched CureDuchenne Ventures, a new initiative to identify and develop a robust pipeline of therapies to treat Duchenne, the most common and lethal form of muscular dystrophy. This drug discovery and development initiative is based on CureDuchenne’s venture philanthropy model, in which the organization provides early stage funding to biotechnology, pharmaceutical companies and academic investigators to help develop breakthrough therapies to treat Duchenne.